US Patent:
20100260673, Oct 14, 2010
Inventors:
QIZHEN CAO - MOUNTAIN VIEW CA, US
XIAOYUAN CHEN - UNION CITY CA, US
International Classification:
A61K 51/00
C12Q 1/70
C12N 7/00
C07K 7/08
A61K 38/10
A61K 49/00
A61P 35/00
A61B 5/055
US Classification:
424 169, 435 5, 4352351, 530327, 514 14, 424 91, 424 96, 424 93
Abstract:
Rapid assessment of cancer response to a therapeutic regimen can determine efficacy early in the course of treatment. Briefly described, embodiments of this disclosure, among others, encompass a class of molecular imaging probes that can predict tumor early responses to anti-angiogenic therapies, such as that based on Bevacizumab (AVASTIN™). In particular, the present disclosure provides peptides that selectively bind to vascularized taget tissues such as, but not limited to solid tumors, responsive to anti-angiogenic therapies and which can, therefore, be useful to selectively concentrate moieties such as detectable labels, or therapeutic agents, in a tumor. The detectable labels, therefore, provide a way to selectively detect and monitor tissues, and most advantageously tumors, that respond to anti-angiogenic therapies.
